Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Predictive Oncology (NASDAQ: POAI) has completed the sale of its Skyline Medical subsidiary's assets to DeRoyal Industries, a global medical products manufacturer. The transaction involves the STREAMWAY® System, an FDA-cleared direct-to-drain wall suction waste fluid management technology.
The sale aligns with POAI's strategic focus on AI-driven drug discovery and comes ahead of its planned merger with Renovaro Biosciences. The company had implemented a restructuring plan for Skyline Medical in late 2023, successfully returning the unit to profitability by the end of 2024.
DeRoyal Industries will integrate the STREAMWAY® System into its product portfolio under its own brand, maintaining service continuity for existing customers while expanding market reach. The system provides healthcare professionals with an automated solution for managing potentially hazardous fluids during medical procedures, designed to reduce manual handling and eliminate spillage risks.
Predictive Oncology (NASDAQ: POAI) ha completato la vendita degli attivi della sua controllata Skyline Medical a DeRoyal Industries, un produttore globale di prodotti medicali. La transazione riguarda il STREAMWAY® System, una tecnologia di gestione dei fluidi di scarto per aspirazione a parete diretta al drenaggio, approvata dalla FDA.
La vendita è in linea con il focus strategico di POAI sulla scoperta di farmaci guidata dall'IA e avviene in vista della sua fusione pianificata con Renovaro Biosciences. L'azienda aveva implementato un piano di ristrutturazione per Skyline Medical alla fine del 2023, riuscendo a riportare l'unità alla redditività entro la fine del 2024.
DeRoyal Industries integrerà il STREAMWAY® System nel proprio portafoglio prodotti sotto il proprio marchio, mantenendo la continuità del servizio per i clienti esistenti mentre espande la portata di mercato. Il sistema fornisce ai professionisti della salute una soluzione automatizzata per gestire fluidi potenzialmente pericolosi durante le procedure mediche, progettata per ridurre il maneggiamento manuale e eliminare i rischi di fuoriuscita.
Predictive Oncology (NASDAQ: POAI) ha completado la venta de los activos de su filial Skyline Medical a DeRoyal Industries, un fabricante global de productos médicos. La transacción involucra el STREAMWAY® System, una tecnología de gestión de fluidos de desecho de succión de pared directa al drenaje, aprobada por la FDA.
La venta se alinea con el enfoque estratégico de POAI en el descubrimiento de fármacos impulsado por IA y se lleva a cabo antes de su fusión planificada con Renovaro Biosciences. La compañía había implementado un plan de reestructuración para Skyline Medical a finales de 2023, logrando devolver la unidad a la rentabilidad para finales de 2024.
DeRoyal Industries integrará el STREAMWAY® System en su cartera de productos bajo su propia marca, manteniendo la continuidad del servicio para los clientes existentes mientras amplía su alcance en el mercado. El sistema proporciona a los profesionales de la salud una solución automatizada para gestionar fluidos potencialmente peligrosos durante los procedimientos médicos, diseñado para reducir el manejo manual y eliminar los riesgos de derrames.
Predictive Oncology (NASDAQ: POAI)는 자회사인 Skyline Medical의 자산을 글로벌 의료 제품 제조업체인 DeRoyal Industries에 매각했다고 발표했습니다. 이번 거래는 FDA 승인을 받은 STREAMWAY® System, 즉 직접 배수 벽 흡입 폐액 관리 기술과 관련이 있습니다.
이번 매각은 POAI의 AI 기반 약물 발견에 대한 전략적 초점과 일치하며, Renovaro Biosciences와의 계획된 합병에 앞서 이루어졌습니다. 회사는 2023년 말 Skyline Medical에 대한 구조조정 계획을 시행하여 2024년 말까지 해당 사업부를 수익성으로 되돌리는 데 성공했습니다.
DeRoyal Industries는 STREAMWAY® System을 자사 브랜드로 제품 포트폴리오에 통합하여 기존 고객에게 서비스 연속성을 유지하면서 시장 범위를 확장할 것입니다. 이 시스템은 의료 절차 중 잠재적으로 위험한 액체를 관리하기 위한 자동화 솔루션을 의료 전문가에게 제공하며, 수동 처리의 필요성을 줄이고 유출 위험을 제거하도록 설계되었습니다.
Predictive Oncology (NASDAQ: POAI) a finalisé la vente des actifs de sa filiale Skyline Medical à DeRoyal Industries, un fabricant mondial de produits médicaux. La transaction concerne le STREAMWAY® System, une technologie de gestion des fluides de déchets par aspiration murale directe vers le drain, approuvée par la FDA.
La vente s'inscrit dans la stratégie de POAI axée sur la découverte de médicaments assistée par IA et intervient avant sa fusion prévue avec Renovaro Biosciences. L'entreprise avait mis en œuvre un plan de restructuration pour Skyline Medical fin 2023, réussissant à ramener l'unité à la rentabilité d'ici fin 2024.
DeRoyal Industries intégrera le STREAMWAY® System dans son portefeuille de produits sous sa propre marque, tout en maintenant la continuité du service pour les clients existants et en élargissant sa portée sur le marché. Le système offre aux professionnels de la santé une solution automatisée pour gérer des fluides potentiellement dangereux lors des procédures médicales, conçue pour réduire la manipulation manuelle et éliminer les risques de déversement.
Predictive Oncology (NASDAQ: POAI) hat den Verkauf der Vermögenswerte ihrer Tochtergesellschaft Skyline Medical an DeRoyal Industries, einen globalen Hersteller medizinischer Produkte, abgeschlossen. Die Transaktion betrifft das STREAMWAY® System, eine von der FDA genehmigte Technologie zur Abfallflüssigkeitsmanagement über Wandabsaugung direkt zum Abfluss.
Der Verkauf steht im Einklang mit dem strategischen Fokus von POAI auf KI-gesteuerte Arzneimittelentdeckung und erfolgt vor der geplanten Fusion mit Renovaro Biosciences. Das Unternehmen hatte Ende 2023 einen Restrukturierungsplan für Skyline Medical umgesetzt und die Einheit bis Ende 2024 erfolgreich wieder profitabel gemacht.
DeRoyal Industries wird das STREAMWAY® System in sein Produktportfolio unter eigener Marke integrieren, um die Servicekontinuität für bestehende Kunden zu gewährleisten und gleichzeitig die Marktpräsenz zu erweitern. Das System bietet Gesundheitsfachkräften eine automatisierte Lösung zur Verwaltung potenziell gefährlicher Flüssigkeiten während medizinischer Eingriffe, die darauf ausgelegt ist, den manuellen Umgang zu reduzieren und das Risiko von Verschüttungen zu beseitigen.
- Successfully restructured and returned Skyline Medical to profitability by end of 2024
- Strategic divestment allows focus on core AI-driven drug discovery business
- Asset sale to established market leader DeRoyal Industries enhances product distribution potential
- Reduction in business diversification with the sale of revenue-generating subsidiary
Insights
Predictive Oncology's divestiture of its Skyline Medical assets represents a significant strategic realignment that sharpens the company's focus on its core AI-driven drug discovery business. This transaction appears well-timed and strategically sound for several reasons.
First, management demonstrated business discipline by restructuring Skyline Medical in late 2023 to improve its operating metrics and restore profitability before selling - essentially maximizing the unit's value prior to divestiture. This suggests thoughtful capital allocation and strategic planning.
Second, this transaction removes operational complexity ahead of POAI's pending merger with Renovaro Biosciences, creating a more streamlined entity focused exclusively on AI-driven drug discovery. For a micro-cap company with
While financial terms weren't disclosed (a notable omission), the deal likely improves POAI's capital structure ahead of the Renovaro merger. By divesting a non-core asset that required separate operational focus, POAI can now direct all resources toward their proprietary AI technology for drug discovery - a higher-margin business with potentially greater scalability than medical equipment.
The buyer, DeRoyal Industries, gains an FDA-cleared medical waste management system that complements their existing healthcare product portfolio, suggesting they may be better positioned to scale the STREAMWAY technology.
This asset sale represents a critical step in Predictive Oncology's transformation into a pure-play AI drug discovery company. The STREAMWAY System, while innovative in medical waste management, had technological synergy with POAI's core artificial intelligence platform.
The strategic rationale is compelling: POAI is doubling down on its computational drug discovery capabilities - where the real technological value proposition lies. AI-driven drug discovery represents a higher-value technological frontier than medical device manufacturing, with potential to exponentially accelerate the identification of promising cancer therapies while reducing R&D costs.
This technology focus will likely enhance POAI's integration with Renovaro Biosciences, potentially creating a more cohesive platform leveraging complementary AI capabilities. While the STREAMWAY System addressed important clinical waste management needs, it operated in a fundamentally different technological ecosystem requiring separate R&D investments, regulatory approaches, and commercialization strategies.
For DeRoyal, acquiring the STREAMWAY technology provides immediate access to an established, FDA-cleared system they can integrate into their broader healthcare product portfolio. The transition to DeRoyal branding indicates they intend to fully incorporate and potentially expand this technology within their existing sales channels.
This transaction represents a technology strategy alignment that positions POAI to concentrate its resources on its most promising technological differentiation in the competitive AI drug discovery landscape.
Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth
Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery capabilities and integrate seamlessly with Renovaro Biosciences
PITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has completed the sale of assets related to its wholly owned subsidiary, Skyline Medical Inc., to DeRoyal Industries, Inc., a global manufacturer and supplier of medical products.
As previously disclosed, Skyline Medical’s business operated outside the core focus of Predictive Oncology, which is the use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients. This transaction was consummated in anticipation of Predictive Oncology’s previously announced merger with Renovaro Biosciences.
Headquartered in Eagan, Minnesota, Skyline Medical markets and sells the FDA-cleared STREAMWAY® System, a direct-to-drain wall suction waste fluid management technology that provides healthcare professionals with an automated, secure, and reliable method for managing potentially hazardous fluids, such as those generated during surgeries or other medical procedures. The system is designed to reduce manual handling, eliminate fluid spillage risks, and streamline waste management operations within medical settings.
“In late 2023, we implemented a restructuring plan with Skyline Medical to dramatically improve its operating metrics and return the business unit to profitability,” stated Josh Blacher, Chief Financial Officer of Predictive Oncology. “Having largely achieved this goal by the end of 2024, we then looked to consummate a synergistic business combination with an industry leader that would enable Skyline Medical to reach its full potential. That is exactly what this transaction with DeRoyal represents.”
"We are excited to integrate this innovative wall suction waste fluid management system into our product offerings," said Chris Schulze, Chief Sales Officer of DeRoyal Industries. "This acquisition strengthens our position as a leader in healthcare waste management solutions, enabling us to better serve our customers with advanced, environmentally friendly technologies. The Streamway® product line aligns with DeRoyal’s commitment to improving the safety, efficiency, and sustainability of healthcare facilities, while also supporting their efforts to meet regulatory compliance standards."
As part of the acquisition, DeRoyal Industries will offer the Streamway® wall suction waste fluid management product line under the DeRoyal brand. This transition will ensure seamless continuity for Skyline Medical’s existing customers while expanding the product's reach to new healthcare facilities looking to enhance their fluid waste management systems. The transaction was accounted for as an asset sale and all necessary approvals have been previously obtained.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with
About DeRoyal Industries
DeRoyal Industries, Inc. is a leading manufacturer and supplier of innovative healthcare products and services. For over 50 years, DeRoyal has been dedicated to providing high-quality solutions that improve patient outcomes, enhance the efficiency of healthcare providers, and support the success of healthcare facilities worldwide. The company offers a wide range of products including surgical, wound care, infection prevention, and waste management solutions.
Investor Relations Contact:
Michael Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.
FAQ
What assets did Predictive Oncology (POAI) sell to DeRoyal Industries?
How did POAI's restructuring of Skyline Medical in 2023 perform?
What will happen to existing Skyline Medical customers after the DeRoyal acquisition?
How does the Skyline Medical sale align with POAI's business strategy?
